companydata.dkcompanydata.dk

Afyx Therapeutics A/S: Financial statements 2022

CVR: 38793594

Source: annual report 2022, Danish Business Authority

01/01/2022 – 31/12/2022

Afyx Therapeutics A/S (CVR 38793594) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -3,222,038 and a net result of DKK -7,273,933 compared with DKK -814,180 the year before. Equity in the 2022 report amounted to DKK -1,031,086. The company had 3 employees in the financial year.

Gross Profit
DKK -3,222,038
Profit/Loss
DKK -7,273,933
Equity
DKK -1,031,086
Total Assets
DKK 13,406,817
Employees
3

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2022--3.2M-7.3M-1M3
2021-1.5M-814K6.2M2
2020--586K-1.5M4.7M2
2019--1.1M-1.6M1M1

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on Afyx Therapeutics A/S

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2022

Afyx Therapeutics A/S: The 2021 annual report is outJun 28, 2022

Afyx Therapeutics A/S has published its annual report for 2021. Gross profit came to DKK 1,509,144, and the net result was DKK -814,180.

About Afyx Therapeutics A/S

Afyx Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2017. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Inphena A/S and Inphena ApS. The management consists of Claus Juan Møller-San Pedro. The board consists of Ole Baadsgaard (chair), Claus Juan Møller-San Pedro, Pia Leah Møller-San Pedro and Søren Mohrsen Kjær. The company is owned by Afyx Capital ApS. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK 23,138,320 and a net result of DKK 1,518,132 compared with DKK -3,810,585 the year before. Equity in the 2025 report amounted to DKK 36,178,254.

Source: annual report 2025, Danish Business Authority

Other financial years